Abstract
The systemic targeting of the VEGF pathway has, in recent years, been used to successfully treat a number of solid cancers. Drugs that target this pathway—which include the antibody bevacizumab—disrupt angiogenesis in the tumor. However, the VEGF pathway also has a role in cardiac physiology, which may explain some of the reported adverse effects of VEGF-targeted agents that include hypertension, and arterial and venous thromboembolism.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
